XML 162 R146.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and Contingencies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jul. 06, 2020
Dec. 13, 2019
Nov. 07, 2018
Jul. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Jun. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Aug. 13, 2020
Jan. 02, 2019
Concentration risk percentage         100.00% 100.00%   100.00% 100.00% 100.00% 100.00%    
Operating lease liabilities         $ 5,000     $ 5,000   $ 3,300,000 $ 3,458,000   $ 3,458,000
Brooklyn Immunotherapeutics, LLC [Member]                          
Sublease payments               58,957 $ 6,535        
Operating lease liabilities         $ 100,700     $ 100,700   $ 103,056      
Brooklyn Immunotherapeutics, LLC [Member] | USF License Agreement [Member]                          
Royalty payable percentage                   7.00%      
Brooklyn Immunotherapeutics, LLC [Member] | IRX Royalty Agreements [Member]                          
Concentration risk percentage                   1.00%      
Brooklyn Immunotherapeutics, LLC [Member] | Termination Agreement [Member]                          
Concentration risk percentage             6.00%            
Brooklyn Immunotherapeutics, LLC [Member] | Investor Royalty Agreement [Member]                          
Concentration risk percentage     4.00%                    
Brooklyn Immunotherapeutics, LLC [Member] | CEO Separation Agreement [Member] | Chief Executive Officer [Member]                          
Severance pay   $ 225,000   $ 275,000                  
Unused vacation time   37,518                      
Health and dental insurance plan   $ 14,032                      
Brooklyn Immunotherapeutics, LLC [Member] | IRX Therapeutics, Inc [Member]                          
Business combination percentage                   25.00%      
Legal settlements                       $ 150,000  
Brooklyn Immunotherapeutics, LLC [Member] | BIT Merger Sub, Inc [Member] | Employee Agreements [Member] | Chief Executive Officer [Member] | January 8, 2021 [Member]                          
Employee, retention payment $ 200,000                        
Brooklyn Immunotherapeutics, LLC [Member] | BIT Merger Sub, Inc [Member] | Employee Agreements [Member] | Chief Executive Officer [Member] | July 8, 2021 [Member]                          
Employee, retention payment $ 200,000